Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus BETOPTIC S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus BETOPTIC S.
BETAPACE vs BETOPTIC S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Betaxolol is a cardioselective beta-1 adrenergic receptor antagonist. In ophthalmic use, it reduces intraocular pressure by decreasing the production of aqueous humor, likely through blockade of beta-2 receptors in the ciliary epithelium.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
Instill 1 drop in the affected eye(s) twice daily.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life is approximately 4–6 hours in adults; prolonged in renal impairment and in elderly patients due to decreased clearance.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Renal: 0.3% unchanged; extensive hepatic metabolism to inactive metabolites; biliary/fecal elimination of metabolites accounts for the majority of excretion; total renal elimination of drug and metabolites is approximately 80%, with the remainder via feces.
Category C
Category C
Beta-Blocker
Beta-Blocker